- 1D
- 5D
- 1M
- 6M
- 1Y
- 5Y
Price Range
- 1D
- 5D
- 1M
- 6M
- 1Y
- 5Y
Price Range
Key Metrics
- Market Cap (In Cr) 72246.41
- Beta 0.23
- Div. Yield (%) 0.69
- P/B 3.76
- TTM P/E 19.3
- Peg Ratio 1.85
- Sector P/E 30.05
- D/E -
- Open Price 4332.05
- Prev Close 4350.05
Analysis
-
1 Week0.48%
-
3 Months-3.03%
-
6 Month2.99%
-
YTD2.64%
-
1 Year-0.06%
- 18% Low risk
- 18% Moderate risk
- 18% Balanced Risk
- 18% High risk
- 18% Extreme risk
40 Analysts
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
- Ratings
- Current
- Strong Sell
- 1
- Sell
- 2
- Hold
- 6
- Buy
- 17
- Strong Buy
- 14
Dr Reddys Laboratories News
Dr Reddy's shares continue to bleed. Is it a 'buy on dip' opportunity?
3 min read . 28 Jul 2021DRL, Cipla, 3 more pharma firms tie-up for trial of oral covid drug
1 min read . 29 Jun 2021Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2022
- Total Revenue
- 21545.2
- Selling/ General/ Admin Expenses Total
- 7339.9
- Depreciation/ Amortization
- 1165.2
- Total Operating Expense
- 18942.7
- Operating Income
- 2602.5
- Net Income Before Taxes
- 3061.4
- Net Income
- 2182.5
- Diluted Normalized EPS
- 165.95
- Period
- 2022
- Total Assets
- 29746.9
- Total Liabilities
- 10534.5
- Total Equity
- 19212.4
- Tangible Book Valueper Share Common Eq
- 961.93
- Period
- 2022
- Cashfrom Operating Activities
- 2810.8
- Cashfrom Investing Activities
- -2638.7
- Cashfrom Financing Activities
- -242.2
- Net Changein Cash
- 3.2
- Period
- 2021
- Total Revenue
- 19047.5
- Selling/ General/ Admin Expenses Total
- 6385.1
- Depreciation/ Amortization
- 1228.8
- Total Operating Expense
- 16402.2
- Operating Income
- 2645.3
- Net Income Before Taxes
- 2883.5
- Net Income
- 1951.6
- Diluted Normalized EPS
- 142.73
- Period
- 2021
- Total Assets
- 26616.8
- Total Liabilities
- 8975.1
- Total Equity
- 17641.7
- Tangible Book Valueper Share Common Eq
- 818.04
- Period
- 2021
- Cashfrom Operating Activities
- 3570.3
- Cashfrom Investing Activities
- -2266
- Cashfrom Financing Activities
- -29.8
- Net Changein Cash
- 1285.8
- Period
- 2020
- Total Revenue
- 17517
- Selling/ General/ Admin Expenses Total
- 5881
- Depreciation/ Amortization
- 1163.1
- Total Operating Expense
- 16203
- Operating Income
- 1314
- Net Income Before Taxes
- 1885.7
- Net Income
- 2026
- Diluted Normalized EPS
- 187.62
- Period
- 2020
- Total Assets
- 23225.3
- Total Liabilities
- 7626.5
- Total Equity
- 15598.8
- Tangible Book Valueper Share Common Eq
- 749.67
- Period
- 2020
- Cashfrom Operating Activities
- 2984.1
- Cashfrom Investing Activities
- -492.3
- Cashfrom Financing Activities
- -2515.9
- Net Changein Cash
- -26.6
- Period
- 2019
- Total Revenue
- 15448.2
- Selling/ General/ Admin Expenses Total
- 5839.9
- Depreciation/ Amortization
- 1134.8
- Total Operating Expense
- 13404.8
- Operating Income
- 2043.4
- Net Income Before Taxes
- 2292
- Net Income
- 1950
- Diluted Normalized EPS
- 111.64
- Period
- 2019
- Total Assets
- 22465.6
- Total Liabilities
- 8442
- Total Equity
- 14023.6
- Tangible Book Valueper Share Common Eq
- 559.81
- Period
- 2019
- Cashfrom Operating Activities
- 2870.4
- Cashfrom Investing Activities
- -772.7
- Cashfrom Financing Activities
- -2132.6
- Net Changein Cash
- -31.4
- Period
- 2018
- Total Revenue
- 14281
- Selling/ General/ Admin Expenses Total
- 5670.3
- Depreciation/ Amortization
- 1077.2
- Total Operating Expense
- 13007
- Operating Income
- 1274
- Net Income Before Taxes
- 1350.4
- Net Income
- 946.8
- Diluted Normalized EPS
- 64.61
- Period
- 2018
- Total Assets
- 22544.3
- Total Liabilities
- 9972.7
- Total Equity
- 12571.6
- Tangible Book Valueper Share Common Eq
- 474.6
- Period
- 2018
- Cashfrom Operating Activities
- 1803
- Cashfrom Investing Activities
- -1488.3
- Cashfrom Financing Activities
- -444
- Net Changein Cash
- -123.6
- Period
- 2017
- Total Revenue
- 14196.1
- Selling/ General/ Admin Expenses Total
- 5605.4
- Depreciation/ Amortization
- 1026.6
- Total Operating Expense
- 12743.4
- Operating Income
- 1452.7
- Net Income Before Taxes
- 1553.7
- Net Income
- 1292.1
- Diluted Normalized EPS
- 81.14
- Period
- 2017
- Total Assets
- 21816.5
- Total Liabilities
- 9554.4
- Total Equity
- 12262.1
- Tangible Book Valueper Share Common Eq
- 461.23
- Period
- 2017
- Cashfrom Operating Activities
- 2144.5
- Cashfrom Investing Activities
- -1840.4
- Cashfrom Financing Activities
- -369.2
- Net Changein Cash
- -114.3
- Period
- 2022-12-31
- Total Revenue
- 6789.8
- Selling/ General/ Admin Expenses Total
- 2836.5
- Depreciation/ Amortization
- 323.7
- Total Operating Expense
- 5175
- Operating Income
- 1614.8
- Net Income Before Taxes
- 1637.7
- Net Income
- 1243.9
- Diluted Normalized EPS
- 75.37
- Period
- 2022-12-31
- Period
- 2022-12-31
- Period
- 2022-09-30
- Total Revenue
- 6331.8
- Selling/ General/ Admin Expenses Total
- 2583.4
- Depreciation/ Amortization
- 309.2
- Total Operating Expense
- 4742.1
- Operating Income
- 1589.7
- Net Income Before Taxes
- 1613.6
- Net Income
- 1114.2
- Diluted Normalized EPS
- 67.08
- Period
- 2022-09-30
- Total Assets
- 29168.9
- Total Liabilities
- 8393.7
- Total Equity
- 20775.2
- Tangible Book Valueper Share Common Eq
- 1029.64
- Period
- 2022-09-30
- Cashfrom Operating Activities
- 1593.6
- Cashfrom Investing Activities
- 81
- Cashfrom Financing Activities
- -2314.6
- Net Changein Cash
- -575.9
- Period
- 2022-06-30
- Total Revenue
- 5232.9
- Selling/ General/ Admin Expenses Total
- 2368.2
- Depreciation/ Amortization
- 301.8
- Total Operating Expense
- 4581.3
- Operating Income
- 651.6
- Net Income Before Taxes
- 1468
- Net Income
- 1189
- Diluted Normalized EPS
- 71.48
- Period
- 2022-06-30
- Period
- 2022-06-30
- Period
- 2022-03-31
- Total Revenue
- 5474.9
- Selling/ General/ Admin Expenses Total
- 2384.2
- Depreciation/ Amortization
- 293
- Other Operating Expenses Total
- -6.7
- Total Operating Expense
- 5310.2
- Operating Income
- 164.7
- Net Income Before Taxes
- 258.9
- Net Income
- 97
- Diluted Normalized EPS
- 34.78
- Period
- 2022-03-31
- Total Assets
- 29746.9
- Total Liabilities
- 10534.5
- Total Equity
- 19212.4
- Tangible Book Valueper Share Common Eq
- 961.93
- Period
- 2022-03-31
- Cashfrom Operating Activities
- 2810.8
- Cashfrom Investing Activities
- -2638.7
- Cashfrom Financing Activities
- -242.2
- Net Changein Cash
- 3.2
- Period
- 2021-12-31
- Total Revenue
- 5338.3
- Selling/ General/ Admin Expenses Total
- 2303.2
- Depreciation/ Amortization
- 294.2
- Total Operating Expense
- 4416.8
- Operating Income
- 921.5
- Net Income Before Taxes
- 974.2
- Net Income
- 709.3
- Diluted Normalized EPS
- 42.86
- Period
- 2021-12-31
- Period
- 2021-12-31
Forecast
Forecast
Forecast
Technical
- 5 Day4346.78
- 10 Day4319.88
- 20 Day4317.91
- 50 Day4347.58
- 100 Day4350.96
- 300 Day4294.35
Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Cipla
- 1028.15
- -1.6
- -0.16
- 1185.2
- 880
- 82514.33
- Divis Laboratories
- 2770.5
- -7.65
- -0.28
- 4640.95
- 2745.1
- 76570.43
- Dr Reddys Laboratories
- 4423.1
- 73.05
- 1.68
- 4645.55
- 3655
- 72392.58
- Torrent Pharmaceuticals
- 1530.6
- -9.2
- -0.6
- 1722.7
- 1235.88
- 51846.46
- Abbott India
- 20699.95
- -181.4
- -0.87
- 22481.8
- 15426.74
- 44352.08
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Cipla
- 30.72
- 3.96
- 11.75
- 10.53
- Divis Laboratories
- 25.85
- 6.53
- 22.49
- 28.33
- Dr Reddys Laboratories
- 26.26
- 3.76
- 12.1
- 10.32
- Torrent Pharmaceuticals
- 47.8
- 8.71
- 16.36
- 10.81
- Abbott India
- 55.53
- 15.73
- 27.07
- 14.45
Shareholding
- Category
- Percentage
- No. of shares
- Public Shareholding
- 73.05%
- 121,639,750
- FIRST SENTIER INVESTORS ICVC - STEWART INVESTORS ASIA PACIFIC LEADERS SUSTAINABILITY FUND
- 2.2%
- 3,658,520
- GOVERNMENT OF SINGAPORE
- 1.36%
- 2,267,409
- GOVERNMENT PENSION FUND GLOBAL
- 1.06%
- 1,760,157
- Others
- 22.06%
- 36,750,728
- LIFE INSURANCE CORPORATION OF INDIA P & GS FUND
- 8.95%
- 14,896,920
- HDFC LIFE INSURANCE COMPANY LIMITED
- 1.03%
- 1,718,739
- Others
- 2.24%
- 3,741,167
- SBI-ETF NIFTY 50
- 1.57%
- 2,618,721
- HDFC TRUSTEE COMPANY LTD. A/C HDFC NIFTY 50 ETF
- 1.36%
- 2,266,282
- NIPPON LIFE INDIA TRUSTEE LTD-A/C NIPPON INDIA ETF NIFTY 100
- 1.16%
- 1,938,128
- ICICI PRUDENTIAL SENSEX INDEX FUND
- 1.05%
- 1,744,834
- Others
- 5.79%
- 9,649,046
- J P Morgan Chase Bank NA
- 10.53%
- 17,536,620
- Others
- 7.73%
- 12,876,737
- Trusts
- 1.89%
- 3,151,513
- NPS TRUST-A/C HDFC PENSION MANAGEMENT COMPANY LTD SCHEME TAX SAVER- TIER 2
- 1.89%
- 3,139,887
- Unclaimed or Suspense or Escrow Account
- 0.21%
- 346,039
- HUF
- 0.17%
- 283,421
- Clearing Members
- 0.07%
- 113,492
- Others
- 0.92%
- 1,535,242
- Others
- 0.61%
- 1,007,547
- Others
- 0.49%
- 823,453
- Others
- 0.19%
- 323,017
- Others
- 0.14%
- 230,305
- Others
- 0.11%
- 181,982
- Others
- 0.1%
- 174,771
- Others
- 0.03%
- 42,166
- Others
- 0%
- 2,394
- Others
- 0%
- 400
- Non Promoter - Non Public shareholder
- 0.25%
- 422,761
- Others
- 0.25%
- 422,761
- Promoter & Promoter Group Shareholding
- 26.7%
- 44,461,128
- APS Trust (Trustees: G. V. Prasad and Satish Reddy Kallam)
- 20.62%
- 34,345,308
- KALLAM SATISH REDDY HUF (KALLAM SATISH REDDY)
- 3.32%
- 5,523,677
- GUNUPATI VENKATESWARA PRASAD HUF (GUNUPATI VENKATESWARA PRASAD)
- 1.53%
- 2,543,418
- SAMRAJYAM REDDY KALLAM
- 0.67%
- 1,120,499
- SATISH REDDY KALLAM
- 0.54%
- 901,002
- ANURADHA GUNUPATI
- 0.01%
- 9,205
- DEEPTI REDDY KALLAM
- 0%
- 5,140
- G VANI SANJANA REDDY
- 0%
- 5,140
- GUNUPATI MALLIKA REDDY
- 0%
- 5,139
- SHARATHCHANDRA REDDY GUNUPATI
- 0%
- 2,600
Shareholding Pattern
Shareholding Trend
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 25-Jan-23
- Quarterly Results
- 28-Oct-22
- Quarterly Results
- 28-Jul-22
- Quarterly Results
- 19-May-22
- Audited Results & Final Dividend
- 28-Jan-22
- Quarterly Results
- 29-Oct-21
- Quarterly Results
- 27-Jul-21
- Quarterly Results
- 14-May-21
- Audited Results & Final Dividend
- 29-Jan-21
- Quarterly Results
- Meeting Date
- Announced on
- Purpose
- 29-Jul-22
- 20-May-22
- AGM
- 29-Mar-22
- 25-Feb-22
- POM
- 28-Jul-21
- 20-May-21
- AGM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 19-May-22
- -
- 11-Jul-22
- 30
- 14-May-21
- -
- 09-Jul-21
- 25
Company Profile
ABOUT Dr Reddys Laboratories
- Industry Biotechnology & Drugs
- ISIN INE089A01023
- BSE Code 500124
- NSE Code DRREDDY
Dr. Reddy's Laboratories Limited is an India-based pharmaceutical company. The Company’s segments include Global Generics, which is engaged in manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics); Pharmaceutical Services and Active Ingredients (PSAI), which is engaged in manufacturing and marketing active pharmaceutical ingredients and intermediates for finished pharmaceutical products; Proprietary Products, which focuses on research and development of differentiated formulations and Others, which consists of the Company’s wholly-owned subsidiary, Aurigene Discovery Technologies Limited, which is a discovery stage biotechnology company developing novel and therapies in the fields of oncology and inflammation.
MANAGEMENT
- K. Satish Reddy Chairman of the Board
- G. V. Prasad Co-Chairman of the Board, Managing Director
- Erez Israeli Chief Executive Officer
- Parag Agarwal Chief Financial Officer
- Patrick Aghanian Chief Executive Officer, European Generics
- Marc Kikuchi Chief Executive Officer, North America Generics
- M. Ramana Chief Executive Officer, Branded Markets (India and Emerging Markets)
- Deepak Sapra Chief Executive Officer, API and Services
- Archana Bhaskar Chief Human Resource Officer
- Mukesh Rathi Chief Digital and Information Officer
Company Summary
DR REDDYS LABORATORIES SUMMARY
Dr Reddys Laboratories is trading 1.68% upper at Rs 4423.10 as compared to its last closing price. Dr Reddys Laboratories has been trading in the price range of 4468.75 & 4332.05. Dr Reddys Laboratories has given 2.64% in this year & 0.48% in the last 5 days.
Dr Reddys Laboratories has TTM P/E ratio 19.3 as compared to the sector P/E of 30.05. There are 40 analysts who have initiated coverage on Dr Reddys Laboratories. There are 14 analysts who have given it a strong buy rating & 17 analysts have given it a buy rating. 2 analysts have given the stock a sell rating.
The company posted a net profit of 1243.9 Crores in its last quarter.
Listed peers of Dr Reddys Laboratories include Cipla (-0.16%), Divis Laboratories (-0.28%), Dr Reddys Laboratories (1.68%) etc.
Dr Reddys Laboratories has a 26.7% promoter holding & 0.25% public holding.
FAQs about Dr Reddys Laboratories
- 1 analysts have given a strong sell rating
- 2 analysts have given a sell rating
- 6 analysts have given a hold rating
- 17 analysts have given a buy rating
- 14 analysts have given a strong buy rating
- TTM P/E: 19.3
- Sector P/E: 30.05
- Dividend Yield: 0.69%
- D/E ratio: -